Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Discontinued OperationsCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Dividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

Newmont (NEMCL) Share-based Compensation (2016 - 2025)

Newmont has reported Share-based Compensation over the past 17 years, most recently at $28.0 million for Q4 2025.

  • Quarterly results put Share-based Compensation at $28.0 million for Q4 2025, up 21.74% from a year ago — trailing twelve months through Dec 2025 was $99.0 million (up 11.24% YoY), and the annual figure for FY2025 was $99.0 million, up 11.24%.
  • Share-based Compensation for Q4 2025 was $28.0 million at Newmont, up from $23.0 million in the prior quarter.
  • Over the last five years, Share-based Compensation for NEMCL hit a ceiling of $28.0 million in Q4 2025 and a floor of $16.0 million in Q4 2022.
  • Median Share-based Compensation over the past 5 years was $21.0 million (2021), compared with a mean of $20.6 million.
  • Biggest five-year swings in Share-based Compensation: decreased 19.05% in 2021 and later soared 37.5% in 2023.
  • Newmont's Share-based Compensation stood at $17.0 million in 2021, then decreased by 5.88% to $16.0 million in 2022, then soared by 37.5% to $22.0 million in 2023, then grew by 4.55% to $23.0 million in 2024, then rose by 21.74% to $28.0 million in 2025.
  • The last three reported values for Share-based Compensation were $28.0 million (Q4 2025), $23.0 million (Q3 2025), and $27.0 million (Q2 2025) per Business Quant data.